多发性骨髓瘤中[18F]氟脱氧葡萄糖-PET/MRI(CT)新型判读标准(IMPeTUs)的预后价值
该研究纳入58例新诊断多发性骨髓瘤患者,诊断时均行[18F]FDG-PET/MRI和PET/CT检查,随访42个月。PET/MRI IMPeTUs评分预测无进展生存的AUC为0.760,高于PET/CT IMPeTUs评分(0.711)等指标。PET/MRI IMPeTUs评分≥13是PFS的独立危险因素。
要点
- PET/MRI IMPeTUs评分预测PFS的AUC为0.760,优于PET/CT评分(0.711)及SUVmax等指标
- PET/MRI IMPeTUs评分≥13和PET/CT IMPeTUs评分≥10与更差PFS显著相关
- Cox多因素分析显示PET/MRI IMPeTUs评分≥13是PFS的独立危险因素
核心结论
- IMPeTUs标准化了多发性骨髓瘤的[18F]FDG-PET/MRI和PET/CT判读,IMPeTUs评分对预测多发性骨髓瘤预后至关重要,表现优于SUVmax和临床指标。
研究设计与样本
- 共纳入58例新诊断多发性骨髓瘤患者,诊断时均行[18F]FDG-PET/MRI和PET/CT检查(ChiCTR1900022597),所有患者完成42个月随访。
- 采用Kaplan-Meier法进行生存分析,采用Cox回归进行预后因素的单因素和多因素分析。
主要发现
- ROC曲线显示PET/MRI IMPeTUs评分的曲线下面积为0.760,超过PET/CT IMPeTUs评分(0.711)、PET/CT骨髓SUVmax(0.649)、PET/MRI骨髓SUVmax(0.575)、骨髓浆细胞(0.500)和β2微球蛋白(0.501)。
- 单因素分析和Kaplan-Meier分析显示,PET/MRI IMPeTUs评分≥13和PET/CT IMPeTUs评分≥10与更差的无进展生存显著相关。
- Cox多因素分析显示,PET/MRI IMPeTUs评分≥13是无进展生存的独立危险因素。
关键数值与推荐
- PET/MRI IMPeTUs评分预测PFS的AUC为0.760,PET/CT IMPeTUs评分为0.711,PET/CT骨髓SUVmax为0.649,PET/MRI骨髓SUVmax为0.575,骨髓浆细胞为0.500,β2微球蛋白为0.501。
- PET/MRI IMPeTUs评分≥13和PET/CT IMPeTUs评分≥10与更差的无进展生存显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [18F]fluorodeoxyglucose (FDG)-PET is a powerful tool to evaluate prognosis in multiple myeloma (MM). The development of systematic and reproducible standard interpretation criteria is crucial for the effective application of FDG-PET in MM. A new set of criteria-Italian Myeloma criteria for PET Use (IMPeTUs)-has standardized PET evaluation in MM. However, the prognostic value of IMPeTUs score remains unknown. METHODS: A total of 58 patients with newly diagnosed multiple myeloma (NDMM) who underwent both [18F]FDG-PET/MRI and PET/CT examinations at diagnosis were enrolled (ChiCTR1900022597). All patients completed a 42-month follow-up. The prognostic value of the PET/MRI (or PET/CT) IMPeTUs score in predicting progression-free (PFS) and overall (OS) survival was compared with that of individual laboratory parameters and the maximum standardized uptake value (SUVmax). Kaplan-Meier method was used for survival analysis. Univariate and multivariate analyses of prognostic factors were conducted using Cox regression. RESULTS: ROC curves demonstrated that the area under the curve for the PET/MRI IMPeTUs score was 0.760, exceeding that of the PET/CT IMPeTUs score (0.711), PET/CT BM SUVmax (0.649), PET/MRI BM SUVmax (0.575), bone marrow plasma cells (0.500), and β2-microglobulin (0.501). Univariate analysis and Kaplan-Meier analysis showed that a PET/MRI IMPeTUs score ≥ 13 and PET/CT IMPeTUs score ≥ 10 were significantly associated with worse PFS. Cox multivariate analysis showed that a PET/MRI IMPeTUs score ≥ 13 was an independent risk factor for PFS. CONCLUSION: IMPeTUs standardized [18F]FDG-PET/MRI and PET/CT readings in MM. The IMPeTUs score is crucial for predicting MM prognosis, performing better than SUVmax and clinical indicators. CLINICAL TRIAL REGISTRATION: ChiCTR1900022597, Registered on 18 April 2019.
引用
- Zhang M, Cai T, Jin S, et al. Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma. Eur J Nucl Med Mol Imaging. 2025. PMID: 40175849. doi:10.1007/s00259-025-07219-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。